7 years of historical data (2018–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Atea Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $366M | $282M | $254M | $400M | $789M | $3.4B | — | — |
| Enterprise Value | $303M | $219M | $113M | $-243174698 | $25M | $2.6B | — | — |
| P/E Ratio → | -2.34 | — | — | — | 6.53 | — | — | — |
| P/S Ratio | — | — | — | — | 2.25 | 70.82 | — | — |
| P/B Ratio | 0.90 | 0.64 | 0.46 | 0.63 | 1.11 | 6.29 | — | — |
| P/FCF | — | — | — | — | — | 11.61 | — | — |
| P/OCF | — | — | — | — | — | 11.61 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 0.07 | 53.34 | — | — |
| EV / EBITDA | — | — | — | — | 0.18 | — | — | — |
| EV / EBIT | — | — | — | — | 0.18 | — | — | — |
| EV / FCF | — | — | — | — | — | 8.74 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -33.9% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 52.4% | 21.8% | — | — |
| Operating Margin | — | — | — | — | 39.4% | -22.7% | — | — |
| Net Profit Margin | — | — | — | — | 34.5% | -22.5% | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -33.9% | -33.9% | -22.7% | -17.2% | 19.3% | -3.9% | -68.9% | — |
| ROA | -31.8% | -31.8% | -21.6% | -16.1% | 14.8% | -2.5% | -47.3% | -26.0% |
| ROIC | -36.7% | -36.7% | -59.9% | — | — | — | — | — |
| ROCE | -38.3% | -38.3% | -27.1% | -19.2% | 21.9% | -3.9% | -55.4% | -28.6% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $65M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | 0.00 | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.25 | -1.00 | -1.08 | -1.55 | -1.11 | — |
| Net Debt / EBITDA | — | — | — | — | -5.52 | — | — | — |
| Debt / FCF | — | — | — | — | — | -2.87 | — | — |
| Interest Coverage | — | — | — | -11.72 | — | — | — | — |
Net cash position: cash ($65M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
Atea Pharmaceuticals, Inc.'s current ratio of 24.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 35.77x to 24.85x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 24.85 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 |
| Quick Ratio | 24.85 | 24.85 | 18.24 | 35.77 | 13.58 | 2.73 | 9.00 | 19.71 |
| Cash Ratio | 24.44 | 24.44 | 17.86 | 35.00 | 13.44 | 2.69 | 8.90 | 19.60 |
| Asset Turnover | — | — | — | — | 0.45 | 0.06 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 43.64 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Atea Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 15.3% | — | — | — |
| FCF Yield | — | — | — | — | — | 8.6% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $84M | $83M | $83M | $88M | $82M | $83M | $10M |
Compare AVIR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| AVIRYou | $366M | -2.3 | — | — | — | — | -33.9% | -36.7% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 7 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how AVIR stacks up against sector leader BioNTech SE.
Start ComparisonAtea Pharmaceuticals, Inc.'s current P/E ratio is -2.3x. The historical average is 6.5x.
Atea Pharmaceuticals, Inc.'s return on equity (ROE) is -33.9%. The historical average is -21.2%.
Based on historical data, Atea Pharmaceuticals, Inc. is trading at a P/E of -2.3x. Compare with industry peers and growth rates for a complete picture.